EUVIMEDEUVIMED entdecken
VergleichsstudieLeserbriefOpen Access

CSF ctDNA Molecular Clearance as a Prognostic Biomarker for Orelabrutinib‐Treated Primary Central Nervous System Lymphoma: Insights From Comparison With PET ‐ CT

Lixia Sheng, Huijie Hu, Yanli Lai, Shuyan Wang, Di Wang, Shanhao Tang iD, Kaihong Xu, Yongcheng Sun, Ping Zhang, Binbin Lai, Li Hu, Lieguang Chen und 5 weitere

American Journal of Hematology · 2026

DOI: 10.1002/ajh.70402 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Lixia Sheng und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo, China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Central Nervous System Neoplasms, Circulating Tumor DNA, Lymphoma. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Zhejiang Basic Public Welfare Research Project, Natural Science Foundation of Ningbo Municipality, Ningbo Science and Technology Plan Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorCentral Nervous System NeoplasmsCirculating Tumor DNALymphomaPositron Emission Tomography Computed TomographyAgedFemaleHumansMaleMiddle AgedPrognosisProspective StudiesPiperidinesPyridines

Stichwörter der Autor:innen

cerebrospinal fluidcirculating tumor DNAprimary central nervous system lymphomaprognostic biomarkerresponse ratesurvival

Substanzen

Biomarkers, TumorCirculating Tumor DNAorelabrutinibPiperidinesPyridines

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo, China.
  • School of Medicine, Ningbo University, Ningbo, China.
  • Department of Histopathology, Ningbo Clinical Pathology Diagnosis Center, Ningbo, China.
  • Department of Medical, Nanjing Geneseeq Technology Inc., Nanjing, China.
  • Department of Gastrointestinal Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, China.
  • Department of Radiology, The First Affiliated Hospital of Ningbo University, Ningbo, China.

ORCID-Profile: Shanhao Tang, Guifang Ouyang

Förderung

  • Zhejiang Basic Public Welfare Research Project
  • Natural Science Foundation of Ningbo Municipality
  • Ningbo Science and Technology Plan Project
  • Central Nervous System Drugs Key Laboratory of Sichuan Province
  • Basic Public Welfare Research Program of Zhejiang Province

Zitieren

APA

Sheng, L., Hu, H., Lai, Y., Wang, S., Wang, D., Tang, S., Xu, K., Sun, Y., Zhang, P., Lai, B., Hu, L., Chen, L., Pan, Y., Nie, S., Gao, X., Fan, L., & Ouyang, G. (2026). CSF ctDNA Molecular Clearance as a Prognostic Biomarker for Orelabrutinib‐Treated Primary Central Nervous System Lymphoma: Insights From Comparison With PET ‐ CT. American Journal of Hematology. https://doi.org/10.1002/ajh.70402

Vancouver

Sheng L, Hu H, Lai Y, Wang S, Wang D, Tang S, et al. CSF ctDNA Molecular Clearance as a Prognostic Biomarker for Orelabrutinib‐Treated Primary Central Nervous System Lymphoma: Insights From Comparison With PET ‐ CT. American Journal of Hematology. 2026. doi:10.1002/ajh.70402

BibTeX
@article{Sheng2026,
  author = {Sheng, Lixia and Hu, Huijie and Lai, Yanli and Wang, Shuyan and Wang, Di and Tang, Shanhao and Xu, Kaihong and Sun, Yongcheng and Zhang, Ping and Lai, Binbin and Hu, Li and Chen, Lieguang and Pan, Yuning and Nie, Sheng and Gao, Xiang and Fan, Lei and Ouyang, Guifang},
  title = {CSF ctDNA Molecular Clearance as a Prognostic Biomarker for Orelabrutinib‐Treated Primary Central Nervous System Lymphoma: Insights From Comparison With PET ‐ CT},
  journal = {American Journal of Hematology},
  year = {2026},
  doi = {10.1002/ajh.70402}
}
Kostenlos starten →